QP Forum 2011

Article

Over the past few years the role and duties of the Qualified Person keep increasing in significance and scope. Being the key person in the quality function of a pharmaceutical company, the QP has to consider many issues to fulfil the responsibilities and to comply with European legislation.

Budapest, Hungary, 1–2 December 2011

Over the past few years the role and duties of the Qualified Person keep increasing in significance and scope. Being the key person in the quality function of a pharmaceutical company, the QP has to consider many issues to fulfil the responsibilities and to comply with European legislation.

To help European QPs to stay on top of current developments as well as to enable them to network and exchange personal experience and information, the European QP Association specifically developed the QP Forum. This Forum has become the meeting place for QPs and aspiring QPs from Europe and beyond. The annual meeting also addresses upper management functions and authority representatives, though, who want to be informed about the latest development regarding the duties and responsibilities of Qualified Persons.

Like every year, representatives from authorities as well as QPs and well-known experts will present latest issues and share their point of view during this year’s Forum scheduled in Budapest, Hungary, from 1-2 December. During the two pre-conference sessions on 30 November and the six parallel sessions as part of the Forum, various case studies will be presented and discussed to come up with possible solutions.

Contact details

To find out more, please contact
European QP Association
info@qp-association.eu

www.qp-forum.org

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Related Content